Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.43, for a total transaction of $3,528,600.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at approximately $94,244,671.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Illumina, Inc. (NASDAQ:ILMN) opened at 194.47 on Friday. Illumina, Inc. has a one year low of $119.37 and a one year high of $198.55. The firm’s 50-day moving average is $174.66 and its 200 day moving average is $171.89. The firm has a market capitalization of $28.39 billion, a price-to-earnings ratio of 39.02 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.86 EPS. Analysts forecast that Illumina, Inc. will post $3.65 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/05/jay-t-flatley-sells-20000-shares-of-illumina-inc-nasdaqilmn-stock.html.

A number of brokerages have recently commented on ILMN. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday. Cowen and Company reissued an “outperform” rating and issued a $200.00 target price on shares of Illumina in a research note on Wednesday. Deutsche Bank AG set a $175.00 target price on shares of Illumina and gave the company a “hold” rating in a research note on Friday, July 28th. BidaskClub raised shares of Illumina from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, First Analysis raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price on the stock in a research note on Wednesday. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $174.38.

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares during the last quarter. Jennison Associates LLC boosted its position in Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Geode Capital Management LLC boosted its position in Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock valued at $248,460,000 after buying an additional 107,941 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Illumina by 2.5% in the second quarter. Legal & General Group Plc now owns 667,874 shares of the life sciences company’s stock valued at $115,892,000 after buying an additional 16,560 shares during the last quarter. Hedge funds and other institutional investors own 93.68% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.